Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Payables (2016 - 2025)

Historic Payables for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $1.9 billion.

  • Dexcom's Payables fell 3031.01% to $1.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 billion, marking a year-over-year decrease of 3031.01%. This contributed to the annual value of $1.9 billion for FY2025, which is 3031.01% down from last year.
  • Dexcom's Payables amounted to $1.9 billion in Q4 2025, which was down 3031.01% from $3.1 billion recorded in Q3 2025.
  • In the past 5 years, Dexcom's Payables registered a high of $3.1 billion during Q2 2025, and its lowest value of $482.0 million during Q2 2021.
  • Over the past 5 years, Dexcom's median Payables value was $1.5 billion (recorded in 2023), while the average stood at $1.5 billion.
  • Per our database at Business Quant, Dexcom's Payables surged by 19221.64% in 2022 and then crashed by 3031.01% in 2025.
  • Quarter analysis of 5 years shows Dexcom's Payables stood at $573.0 million in 2021, then surged by 192.22% to $1.7 billion in 2022, then dropped by 19.64% to $1.3 billion in 2023, then skyrocketed by 107.32% to $2.8 billion in 2024, then crashed by 30.31% to $1.9 billion in 2025.
  • Its Payables stands at $1.9 billion for Q4 2025, versus $3.1 billion for Q3 2025 and $3.1 billion for Q2 2025.